Resources - COVID-19 information
Section dedicated to information on pharmacovigilance of medicinal products used to treat and prevent COVID-19 (coronavirus).
The section is divided into two parts: one part relating to links to national and international institutional websites on SARS-CoV-2 (COVID-19) and another part relating to important research documents and initiatives from ISoP members and others.
This page will be regularly updated.
Here you will find some links to national and international institutional websites and published papers on COVID-19. Stay informed with the latest clinical research and resources.
World Health Organization
Centers for Disease Control and Prevention
National Institute of Health
European Medicines Agency
COVID-19 data sources (Knowledge Portal on Innovation and Access to Medicines)
The New England Journal Of Medicine
Oxford Covid-19 Evidence service
The Royal College of Obstetricians and Gynaecologists (RCOG)
Italian Society of Pharmacology - English COVID-19 section
International Union of Pharmacology and Clinical Pharmacology (IUPHAR)
NIPH-Live map of COVID-19 evidence
The International Coalition of Medicines Regulatory Authorities (ICMRA)
Safety Monitoring Using WHO Global Database of Individual Case Safety Reports (ICSRs). Descriptive analysis of spontaneous report from VigiBase
Indian Council of Medical Research updated ethical guidance for biomedical and health research
African Vaccine Regulatory Forum (AVAREF) tools for Processing clinical trial applications by Ethics Committees and National Regulatory Authorities in Africa
Landscape of COVID-19 candidate vaccines/Draft
NZ Pharmacovigilance Centre Project encouraging feedback on COVID-19 Medication Safety Challenges in NZ
The Vaccine Centre & London School of Hygiene & Tropical Medicine
Johns Hopkins University-Coronavirus Resource Center
ISoP Member Papers and initiatives
ISoP colleagues in the North American Chapter of ISoP (NASoP) and the Italian Society of Pharmacology (SIF) are working on proposals to monitor the safety of medicines and vaccines to treat and prevent COVID-19. Here you will find also important research documents and initiatives from ISoP members and others.
Official statement of the section of Clinical Pharmacology of the Italian Society of Pharmacology on the use of ACE- inhibitors or angiotensin receptor blockers in COVID-19 infection with commentary
Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary
Simplified description of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Viral lifecycle and drug repurposing strategies
Benefit-Risk evaluation for Remdesivir in COVID-19
The challenging times and opportunities for pharmacovigilance in Africa during the COVID‑19 pandemic
African Chapter of ISoP / Executive Committee
*New ISoP infographic ‘Using Medicines Safely during the COVID-19 pandemic’. This infographic is aimed at patients and caregivers - feel free to display it in hospitals, clinics, pharmacies and any other public spaces appropriate to where medicines are obtained in your country
Posibles terapias para COVID-19: revision narrativa de seguridad I. Cloroquina / hidroxicloroquina y azitromicina
Raquel Herrera Comoglio
The contents of this page are intended for purely informational purposes (the list is not exhaustive).